APA (7th ed.) Citation

Havrdová, E., Belova, A., Goloborodko, A., Tisserant, A., Wright, A., Wallstroem, E., . . . Johns, D. R. (2016). Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: Results from a randomized, proof-of-concept study. Journal of neurology, 263(7), 1287-1295. https://doi.org/10.1007/s00415-016-8128-x

Chicago Style (17th ed.) Citation

Havrdová, Eva, Anna Belova, Alla Goloborodko, Anne Tisserant, Andrew Wright, Erik Wallstroem, Hideki Garren, Ralph Paul Maguire, and Donald R. Johns. "Activity of Secukinumab, an Anti-IL-17A Antibody, on Brain Lesions in RRMS: Results from a Randomized, Proof-of-concept Study." Journal of Neurology 263, no. 7 (2016): 1287-1295. https://doi.org/10.1007/s00415-016-8128-x.

MLA (9th ed.) Citation

Havrdová, Eva, et al. "Activity of Secukinumab, an Anti-IL-17A Antibody, on Brain Lesions in RRMS: Results from a Randomized, Proof-of-concept Study." Journal of Neurology, vol. 263, no. 7, 2016, pp. 1287-1295, https://doi.org/10.1007/s00415-016-8128-x.